Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Chong Ming Yeo

1PUBLICATIONS

17CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Sep 09, 2024

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.

Ross A Soo, Urania Dafni, Ji-Youn Han

Pageof 1

Frequent Collaborators

1 joint publications

Ross A Soo

1 joint publications

Urania Dafni

1 joint publications

Ji-Youn Han

1 joint publications

Byoung Chul Cho

1 joint publications

Ernest Nadal

1 joint publications

Enric Carcereny

1 joint publications

Javier de Castro

1 joint publications

Maria Angeles Sala

1 joint publications

Linda Coate

1 joint publications

Mariano Provencio

Frequent Collaborators

1 joint publications

Ross A Soo

1 joint publications

Urania Dafni

1 joint publications

Ji-Youn Han

1 joint publications

Byoung Chul Cho

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos